Medidata announced a strategic expansion of its partnership with The Menarini Group and Stemline Therapeutics focused on bringing transformational oncology treatments to cancer patients. Through this partnership, Medidata AI Study Build technology will power Stemline’s oncology portfolio to initiate clinical trials faster to meet the urgent needs of people living with cancer. The announcement follows the milestone of Stemline launching its first oncology study entirely in-house, using the Medidata Data Experience.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DASTY:
- Medidata enters collaboration with CRIO
- Dassault Systemes downgraded to Neutral from Buy at Goldman Sachs
- Leadership Transition Risks and Constrained Transformation Capacity Underpin Sell Rating on Dassault Systèmes
- Dassault Systemes price target lowered to EUR 19 from EUR 26 at Citi
- Dassault Systemes price target lowered to EUR 21 from EUR 26 at JPMorgan